Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy

[1] Schultheiss C(2012)Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study Crit Care 16 R162-425

[2] Saugel B(2019)Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis Crit Care 23 22-675

[3] Phillip V(2017)Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction Crit Care 21 294-218

[4] Thies P(2019)Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy J Intensive Care Med 34 418-576

[5] Noe S(2012)Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice Crit Care 16 249-527

[6] Mayr U(2019)The molecular aspect of antitumor effects of protease inhibitor nafamostat mesylate and its role in potential clinical applications Front Oncol 9 852-285

[7] Haller B(2009)Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage Ren Fail 31 668-216

[8] Einwachter H(1999)Inhibitory mechanism of human platelet aggregation by nafamostat mesilate Platelets 10 212-21

[9] Schmid RM(2011)Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study Int J Artif Organs 34 571-105

[10] Huber W(1999)Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate Intensive Care Med 25 524-285

[1] Schultheiss C(2012)Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study Crit Care 16 R162-425

[2] Saugel B(2019)Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis Crit Care 23 22-675

[3] Phillip V(2017)Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction Crit Care 21 294-218

[4] Thies P(2019)Hyperlactatemia predicts citrate intolerance with regional citrate anticoagulation during continuous renal replacement therapy J Intensive Care Med 34 418-576

[5] Noe S(2012)Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice Crit Care 16 249-527

[6] Mayr U(2019)The molecular aspect of antitumor effects of protease inhibitor nafamostat mesylate and its role in potential clinical applications Front Oncol 9 852-285

[7] Haller B(2009)Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage Ren Fail 31 668-216

[8] Einwachter H(1999)Inhibitory mechanism of human platelet aggregation by nafamostat mesilate Platelets 10 212-21

[9] Schmid RM(2011)Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study Int J Artif Organs 34 571-105

[10] Huber W(1999)Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate Intensive Care Med 25 524-285